Therapeutics & Pipeline

Bosakitug Misses Phase 2 Endpoints in Atopic Dermatitis Despite Target Engagement

<![CDATA[Aclaris' Bosakitug Misses Phase 2 Endpoints in Atopic Dermatitis]]>
AI-generated

Bosakitug, Aclaris Therapeutics' investigational anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, failed to meet the primary and secondary endpoints of the phase 2 ADMIRATION trial in moderate to severe atopic dermatitis (AD), the company announced on November 16, 2026.

The primary endpoint — percentage change from baseline in Eczema Area and Severity Index (EASI) score at week 24 — was not achieved. Neither were the secondary endpoints. The drug was generally well tolerated, but tolerability without efficacy is not a development path, and Aclaris did not announce further plans for bosakitug following the readout.

The top-line release was thin on detail. Aclaris provided no numerical efficacy results, no treatment-group comparisons, and no adverse event rates. What the company did disclose, however, is pharmacodynamically significant: analyses showed robust TSLP target engagement and reductions in biomarkers associated with Th1, Th2, and Th17 immune responses.

Why biomarker movement wasn't enough

Bosakitug (ATI-045) is a humanized monoclonal antibody designed to inhibit TSLP, an epithelial-derived cytokine that initiates and amplifies inflammatory responses. TSLP feeds type 2 inflammation, a central driver of AD pathogenesis, which made it a plausible standalone target for patients with moderate-to-severe disease.

The biology worked. The clinical endpoints didn't move. Investigators observed downregulation of T-helper 1, Th2, and Th17 biomarkers, confirming the antibody hit its target, yet those changes did not translate into improvements in disease severity sufficient to meet the prespecified endpoints.

For a field that has watched dupilumab, tralokinumab, and the JAK class reshape AD management, the readout is a blunt reminder that AD runs on multiple redundant inflammatory pathways. Blocking TSLP alone, even with confirmed target engagement, may not be enough to shift EASI scores in a disease where no single cytokine is indispensable.

What does this change for AD clinicians?

Not much at the bedside — and that is the point. No approved therapy changes hands today. The practical takeaway for practitioners is methodological: biomarker modulation is not a surrogate for clinical benefit. Evaluating investigational agents through clinically relevant outcomes — disease severity, symptom burden, tolerability — remains the standard, and the ADMIRATION data reinforce why.

The findings also add to accumulating questions about TSLP inhibition as a monotherapy strategy in AD, distinct from its validated role in asthma.

Where Aclaris goes next

The company says its broader development strategy is unchanged, with continued investment in oral kinase inhibitors and the investigational bispecific antibody ATI-052. The pipeline moves quickly from here:

  • Modzatinib (ATI-2138): A phase 2b trial is underway in lichen planus. The oral inhibitor targets interleukin-2-inducible T-cell kinase (ITK) and Janus kinase 3 (JAK3), pathways involved in T-cell activation and inflammatory signaling.
  • ATI-9494: IND-enabling studies are complete for this oral ITK/TXK inhibitor, with an IND application planned for the fourth quarter of 2026.
  • ATI-052: A phase 2b trial in eosinophilic esophagitis is slated to begin in the first quarter of 2027.

ATI-052 is the instructive one. Unlike bosakitug, which hits TSLP alone, the bispecific antibody targets both TSLP and the interleukin-4 receptor alpha (IL-4Rα), inhibiting two inflammatory signaling pathways at once. Whether dual blockade succeeds where single-target inhibition failed is an open question requiring clinical study.

Aclaris expects several clinical and regulatory milestones across its remaining investigational therapies throughout 2027, and dermatology watchers will be looking to see whether the company's ITK/JAK portfolio can deliver where its TSLP program could not.

Source: dermatologytimes.com

Share this article:

Sophie Lindqvist

Show full bio

Market editor covering people, launches and day-to-day practice in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.

More from Sophie Lindqvist →

Related articles

« Previous articleNext article »